/Edwards%20Lifesciences%20Corp%20Irvine%2C%20Ca%20campus-by%20Steve%20Cukrov%20via%20Shutterstock.jpg)
Edwards Lifesciences Corporation (EW), headquartered in Irvine, California, offers products and technologies for structural heart disease and critical care monitoring. Valued at $41.9 billion by market cap, the company offers products such as tissue replacement heart valves, heart valve repair, hemodynamic monitoring devices, angioscopy equipment, oxygenators, and pharmaceuticals.
Shares of this leading global structural heart innovation company have underperformed the broader market over the past year. EW has declined 16.6% over this time frame, while the broader S&P 500 Index ($SPX) has rallied nearly 20.7%. In 2025, EW stock is down 4.2%, compared to SPX’s 3.2% rise on a YTD basis.